Inovio Pharmaceuticals
130 hedge funds and large institutions have $182M invested in Inovio Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 47 increasing their positions, 29 reducing their positions, and 15 closing their positions.
85% more call options, than puts
Call options by funds: $1.16M | Put options by funds: $626K
62% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 29
60% more capital invested
Capital invested by funds: $113M → $182M (+$68.4M)
27% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 15
3% more funds holding
Funds holding: 126 → 130 (+4)
0.33% more ownership
Funds ownership: 2.65% → 2.98% (+0.33%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$9.42M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$3.35M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.97M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.85M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$1.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$3.89M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1.76M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
-$843K |
| 4 |
Man Group
London,
United Kingdom
|
-$662K |
| 5 |
Squarepoint
New York
|
-$596K |
INO Hedge Fund Activity: Q3 2018 in Review
130 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q3 2018, worth a combined $182M — up 60% from $113M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new INO positions and 15 closed out — a net gain of 4 holders — while 47 added to existing stakes and 29 trimmed.
The largest buyer was Wasatch Advisors, adding an estimated $9.42M. The largest seller was State Street, cutting an estimated $3.89M.
- 130 institutional investors held Inovio Pharmaceuticals (INO) as of Q3 2018, up from 126 in Q2 2018.
- Funds reported $182M of Inovio Pharmaceuticals stock for Q3 2018, up 60% quarter-over-quarter.
- 19 funds opened new Inovio Pharmaceuticals positions in Q3 2018 and 15 closed out, a net change of +4 holders.
- The largest Inovio Pharmaceuticals buyer in Q3 2018 was Wasatch Advisors, an estimated $9.42M added.
- The largest Inovio Pharmaceuticals seller in Q3 2018 was State Street, an estimated $3.89M sold.
Based on aggregated 13F filings for Q3 2018.